Literature DB >> 16251827

Hepatitis B, hepatitis C, and HIV in correctional populations: a review of epidemiology and prevention.

Cindy M Weinbaum1, Keith M Sabin, Scott S Santibanez.   

Abstract

The 2 million persons incarcerated in US prisons and jails are disproportionately affected by hepatitis B virus (HBV), hepatitis C virus (HCV) and HIV, with prevalences of infection two to ten times higher than in the general population. Infections are largely due to sex- and drug-related risk behaviors practised outside the correctional setting, although transmission of these infections has also been documented inside jails and prisons. Public health strategies to prevent morbidity and mortality from these infections should include hepatitis B vaccination, HCV and HIV testing and counseling, medical management of infected persons, and substance abuse treatment in incarcerated populations.

Entities:  

Mesh:

Year:  2005        PMID: 16251827     DOI: 10.1097/01.aids.0000192069.95819.aa

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  51 in total

1.  Predictors of reincarceration and disease progression among released HIV-infected inmates.

Authors:  Jacques Baillargeon; Thomas P Giordano; Amy Jo Harzke; Anne C Spaulding; Z Helen Wu; James J Grady; Gwen Baillargeon; David P Paar
Journal:  AIDS Patient Care STDS       Date:  2010-06       Impact factor: 5.078

2.  From corrections to communities as an HIV priority.

Authors:  David Vlahov; Sara Putnam
Journal:  J Urban Health       Date:  2006-05       Impact factor: 3.671

3.  Modelling alternative strategies for delivering hepatitis B vaccine in prisons: the impact on the vaccination coverage of the injecting drug user population.

Authors:  A J Sutton; N J Gay; W J Edmunds; O N Gill
Journal:  Epidemiol Infect       Date:  2008-03-17       Impact factor: 2.451

4.  Nursing case management, peer coaching, and hepatitis a and B vaccine completion among homeless men recently released on parole: randomized clinical trial.

Authors:  Adeline Nyamathi; Benissa E Salem; Sheldon Zhang; David Farabee; Betsy Hall; Farinaz Khalilifard; Barbara Leake
Journal:  Nurs Res       Date:  2015 May-Jun       Impact factor: 2.381

5.  HIV/STI Risk Behavior of Drug Court Participants.

Authors:  Angela A Robertson; Janet S St Lawrence; D Lee McCluskey
Journal:  J Offender Rehabil       Date:  2012-07

6.  Impact of hepatitis B and C infection on health services utilization in homeless adults: a test of the Gelberg-Andersen Behavioral Model for Vulnerable Populations.

Authors:  Judith A Stein; Ronald M Andersen; Marjorie Robertson; Lillian Gelberg
Journal:  Health Psychol       Date:  2011-05-16       Impact factor: 4.267

7.  Distribution of hepatitis B virus genotypes among patients with chronic infection in Japan shifting toward an increase of genotype A.

Authors:  Kentaro Matsuura; Yasuhito Tanaka; Shuhei Hige; Gotaro Yamada; Yoshikazu Murawaki; Masafumi Komatsu; Tomoyuki Kuramitsu; Sumio Kawata; Eiji Tanaka; Namiki Izumi; Chiaki Okuse; Shinichi Kakumu; Takeshi Okanoue; Keisuke Hino; Yoichi Hiasa; Michio Sata; Tatsuji Maeshiro; Fuminaka Sugauchi; Shunsuke Nojiri; Takashi Joh; Yuzo Miyakawa; Masashi Mizokami
Journal:  J Clin Microbiol       Date:  2009-03-18       Impact factor: 5.948

8.  Treating drug abuse and addiction in the criminal justice system: improving public health and safety.

Authors:  Redonna K Chandler; Bennett W Fletcher; Nora D Volkow
Journal:  JAMA       Date:  2009-01-14       Impact factor: 56.272

9.  Impact of hepatitis B and C co-infection on health-related quality of life in HIV positive individuals.

Authors:  Jennifer Gillis; Curtis Cooper; Sean Rourke; Sergio Rueda; Kelly O'Brien; Evan Collins; Anita Rachlis; Trevor A Hart; Janet Raboud
Journal:  Qual Life Res       Date:  2012-10-17       Impact factor: 4.147

10.  Predictors of drug use in prison among incarcerated Black men.

Authors:  Tawandra L Rowell; Elwin Wu; Carl L Hart; Rahwa Haile; Nabila El-Bassel
Journal:  Am J Drug Alcohol Abuse       Date:  2012-07-02       Impact factor: 3.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.